KEVINA WOODWARD-RILEY: Open Payments
NPI 1164712295 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$493 in 22 payments from 9 companies in 2025. Trend: 2023 $138 · 2024 $306 · 2025 $493
Food & beverage: $493
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $196 |
| GENZYME CORPORATION | 3 | $86 |
| Lilly USA, LLC | 3 | $56 |
| Ardelyx, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 3 | $31 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $24 |
| Janssen Biotech, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
Products named: ENTYVIO, DUPIXENT, OMVOH, IBSRELA, VOQUEZNA, OCALIVA, Wegovy, TREMFYA.
Industry payments across DE — which companies pay providers there.
